These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27742636)

  • 21. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
    Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
    Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.
    McIlleron H; Willemse M; Werely CJ; Hussey GD; Schaaf HS; Smith PJ; Donald PR
    Clin Infect Dis; 2009 Jun; 48(11):1547-53. PubMed ID: 19392636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
    Anderson G; Vinnard C
    J Clin Pharmacol; 2022 Oct; 62(10):1206-1214. PubMed ID: 35588142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study.
    Chiang SS; Starke JR; Miller AC; Cruz AT; Del Castillo H; Valdivia WJ; Tunque G; García F; Contreras C; Lecca L; Alarcón VA; Becerra MC
    Clin Infect Dis; 2016 Oct; 63(8):1063-71. PubMed ID: 27458026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis.
    Shenje J; Ifeoma Adimora-Nweke F; Ross IL; Ntsekhe M; Wiesner L; Deffur A; McIlleron HM; Pasipanodya J; Gumbo T; Mayosi BM
    EBioMedicine; 2015 Nov; 2(11):1640-9. PubMed ID: 26870790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
    Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.
    Zhu M; Starke JR; Burman WJ; Steiner P; Stambaugh JJ; Ashkin D; Bulpitt AE; Berning SE; Peloquin CA
    Pharmacotherapy; 2002 Jun; 22(6):686-95. PubMed ID: 12066959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.
    Zentner I; Modongo C; Zetola NM; Pasipanodya JG; Srivastava S; Heysell SK; Mpagama S; Schlect HP; Gumbo T; Bisson GP; Vinnard C
    Int J Infect Dis; 2018 Mar; 68():18-23. PubMed ID: 29253711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
    Farah MG; Tverdal A; Steen TW; Heldal E; Brantsaeter AB; Bjune G
    BMC Public Health; 2005 Feb; 5():14. PubMed ID: 15698472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
    Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.